
Susumu Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3097676/publications.pdf Version: 2024-02-01



SUSUMU SUZUKI

#	Article	IF	CITATIONS
1	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research, 2015, 21, 4327-4336.	7.0	187
2	Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. Blood, 2017, 130, 1114-1124.	1.4	59
3	Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma. Clinical Cancer Research, 2015, 21, 2830-2839.	7.0	44
4	CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. International Journal of Hematology, 2008, 88, 311-320.	1.6	39
5	Improving function of cytotoxic T″ymphocytes by transforming growth factorâ€Î² inhibitor in oral squamous cell carcinoma. Cancer Science, 2021, 112, 4037-4049.	3.9	31
6	Clinical significance of tryptophan catabolism in Hodgkin lymphoma. Cancer Science, 2018, 109, 74-83.	3.9	25
7	Immuneâ€checkpoint molecules on regulatory Tâ€cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Science, 2020, 111, 1943-1957.	3.9	24
8	Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells. Oncology Reports, 2019, 42, 224-230.	2.6	19
9	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications, 2021, 12, 7280.	12.8	11
10	Combining Tâ€cellâ€based immunotherapy with venetoclax elicits synergistic cytotoxicity to Bâ€cell lines in vitro. Hematological Oncology, 2020, 38, 705-714.	1.7	7
11	CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia. Cell Death Discovery, 2021, 7, 121.	4.7	7
12	Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 10761.	4.1	7
13	Tumorâ€infiltrating <scp>FoxP3</scp> + T cells are associated with poor prognosis in oral squamous cell carcinoma. Clinical and Experimental Dental Research, 2022, 8, 152-159.	1.9	6
14	Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. International Journal of Oncology, 2017, 51, 1471-1481.	3.3	6
15	Clinical significance of tryptophan catabolism in follicular lymphoma. Hematological Oncology, 2020, 38, 742-753.	1.7	4
16	In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients. International Journal of Molecular Sciences, 2022, 23, 4077.	4.1	4
17	Assessment of antibody titer and side effects after third doses of COVID-19 mRNA vaccination in healthy volunteers. Laboratoriums Medizin, 2022, 46, 171-177.	0.6	2
18	The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma. Hemato, 2021, 2, 368-381.	0.6	1

#	Article	IF	CITATIONS
19	ABT-199 (venetoclax) Synergizes Cytotoxicity of Cytotoxic T-Cell (CTL) to B-Cell Lymphomas. Blood, 2018, 132, 5154-5154.	1.4	1
20	A Dynamic Study on the Lumbar Intervertebral Disc. Juntendol̀,, Igaku, 1974, 20, 465-483.	0.1	1